TABLE 1 | Selected antidiabetic drug candidates in Phase II/III testing
From the following article:
Non-insulin therapies for type 2 diabetes
Mona Ashiya & Richard E. T. Smith
Nature Reviews Drug Discovery 6, 777-778 (October 2007)
doi:10.1038/nrd2420
| Name (brand name) | Developer | Phase | Class |
|---|---|---|---|
| Vildagliptin (Galvus) | Novartis | Prereg* | DPP4 inhibitor |
| Saxagliptin | AstraZeneca/Bristol–Myers Squibb | III | DPP4 inhibitor |
| Alogliptin | Takeda | III | DPP4 inhibitor |
| Liraglutide | Novo Nordisk | III | GLP1 analogue |
| Exenatide LAR | Amylin/Eli Lilly | III | GLP1 analogue |
| Dapagliflozin | AstraZeneca/Bristol–Myers Squibb | III | SGLT2 inhibitor |
| GSK716155 | GlaxoSmithKline | II | GLP1 analogue |
| AVE0010 | Sanofi–Aventis | II | GLP1 analogue |
| R1583 | Roche/Ipsen | II | GLP1 analogue |
| CJC-1134-PC | Conjuchem | II | GLP1 analogue |
| AVE2268 | Sanofi–Aventis | II | SGLT2 inhibitor |
| 189075 | GlaxoSmithKline | II | SGLT2 inhibitor |
| R1439 | Roche | II | PPAR / agonist |
| PLX204/PPM-204 | Plexxikon/Wyeth | II | PPAR pan-agonist |
| PSN9301 | OSI Pharmaceuticals | II | DPP4 inhibitor |
| INCB13739 | Incyte | II | HSD11B1 inhibitor |
| R1440/GK3‡ | Roche | II | Glucokinase inhibitor |
*Re-filing in the US expected in mid-2009 pending positive data from a trial in patients who are renally impaired.‡Development of R1440 appears to be discontinued and a backup glucokinase inhibitor has been prioritized for Phase II testing. DPP4, dipeptidyl peptidase 4; GLP1, glucagon-like peptide 1; HSD11B1, hydroxysteroid (11- ) dehydrogenase 1; PPAR, peroxisome proliferator-activated receptor; SGLT2, sodium–glucose co-transporter 2. | |||
Download file
If the slide opens in your browser, select "File > Save As" to save it.
